ANTIBODIES AND ANTI-IDIOTYPES TO NEUROLEPTIC DRUGS

抗多巴胺能(D2)和5-羟色胺(S2)类药物的单抗 (抗精神病药物)和受体将使用独特型策略制造： 抗独特型分子拟态。这种策略使用了一种抗体 (独特型)针对D2或S2拮抗剂(配体)起作用 用于随后生产抗独特型抗体的“模子” 构成反配体结合部位的“内像”，从而 用分子的术语来说，模仿原始的配体。一组克隆的单抗 多巴胺能配体氟哌啶醇和匹莫齐特的抗体已经被 生产的和随后的抗独特型抗体目前正在 测试过。这些受体结合抗体将用于受体 表征、定位和提纯研究。这些研究 将为研究提供有价值的信息工具 独特型：抗独特型模拟和抗受体抗体在糖尿病中的作用 神经系统疾病。

Monoclonal antibodies to dopaminergic (D2) and serotoninergic (S2) drugs (neuroleptics) and receptors will be made using the strategy of idiotype: anti-idiotype molecular mimicry. This strategy employs an antibody (idiotype) directed against D2 or S2 antagonists (ligands) to act as a "mold" for the subsequent production of an anti-idiotype antibody which can constitute an "internal image" of the anti-ligand binding site, and thereby mimic, in molecular terms, the original ligand. A collection of monoclonal antibodies to the dopaminergic ligands haloperidol and pimozide have been produced and subsequent anti-idiotype antibodies are currently being tested. These receptor binding antibodies will be used in receptor characterization, localization and purification studies. These studies will provide valuable information tools for the study of idiotype:anti-idiotype mimicry and the role of anti-receptor antibodies in nervous system diseases.